The project, covering the period 2012-2015, encompasses RDI-related expenditures focusing on formulation and carrier technology for the delivery of medicine and the supporting means necessary to develop innovative products. It will take place in Melsungen (Germany).
Objectives
The project aims to improve quality hospital care products and treatment thanks to the availabilityof leading edge innovative treatments.
Comments
Sector(s)
Industry
Proposed EIB finance (Approximate amount)
EUR 80 million
Total cost (Approximate amount)
EUR 160 million
Environmental aspects
The R&D activities included in this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. Thus, an Environmental Impact Assessment (EIA) according to the Directive 85/337/EC, amended by Directives 97/11/EC and 2003/35/EC, is not required.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The promoter carries out competitive enquiries among potential suppliers for goods and services. These procedures, which are typical for the industry, are in the best interests of the project and entirely satisfactory to the Bank.
Status
Approved
-
20/12/2012.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, EIB can also be contacted through its external offices.
Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.
Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero-tolerance against fraud and corruption
The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.
The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.
